OR
AUCTION DOWN
so we can get to £5.20,£7.50,£12.00 etc etc
not here he dosnt
filtered and deleted
goodbye
Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit
APDN
+8.83%
Mon, November 29, 2021, 11:00 AM
In this article:
APDN
+8.83%
- Linea™ COVID-19 Assay Kit Likely Subject to Unique Double S-Gene Target Drop, Enables Rapid Reflex Testing of Positive Samples to Confirm Probable Presence of Omicron Without Sequencing -
- Company to Submit Validation Data to New York Department of Health for Linea™ 2.0 Assay to Service All safeCircle™ Customers in the Event of Omicron Prevalence -
STONY BROOK, N.Y., November 29, 2021--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced its COVID-19 diagnostic strategy in response to the emergence of Omicron (B.1.1.529), a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea™ 2.0 COVID-19 Assay ("Linea 2.0"), a new RT-PCR assay for the SARS-CoV-2 E and N genes that builds on the Company’s established COVID-19 line of diagnostics, after submission of its validation data to the New York State Department of Health (NYSDOH) in the next few days.
The Company also announced that its EUA-authorized Linea™ COVID-19 Assay Kit (the "Linea 1.0 Assay") likely exhibits a unique double S-gene target failure (or "drop") (SGTF) specific to the Omicron variant. While other assays have been shown to have SGTF based on the presence of the ?69-70 mutation contained in Omicron, this specific mutation is shared across several SARS-CoV-2 lineages and is not specific to the new variant. Based on the Company’s initial analysis, the Company believes that the combination of mutations that cause the unique double SGTF in the Linea 1.0 Assay is unique to Omicron. This unique double SGTF may result in false negative results in patients infected with the Omicron variant when tested with the Linea 1.0 Assay as a primary diagnostic. This unique pattern may, however, allow the Linea 1.0 Assay to provide a high-specificity reflex test for the Omicron variant. More specifically, the Linea 1.0 Assay may be potentially used as a reflex test to indicate the presence of Omicron in samples that have tested positive for COVID-19 via third-party assays that cannot discriminate for the new variant because these same samples will test negative on the Linea 1.0 Assay due to the unique double SGTF.
look it up on Yahoo
Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit
APDN
+8.83%
Mon, November 29, 2021, 11:00 AM
In this article:
APDN
+8.83%
- Linea™ COVID-19 Assay Kit Likely Subject to Unique Double S-Gene Target Drop, Enables Rapid Reflex Testing of Positive Samples to Confirm Probable Presence of Omicron Without Sequencing -
- Company to Submit Validation Data to New York Department of Health for Linea™ 2.0 Assay to Service All safeCircle™ Customers in the Event of Omicron Prevalence -
STONY BROOK, N.Y., November 29, 2021--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced its COVID-19 diagnostic strategy in response to the emergence of Omicron (B.1.1.529), a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea™ 2.0 COVID-19 Assay ("Linea 2.0"), a new RT-PCR assay for the SARS-CoV-2 E and N genes that builds on the Company’s established COVID-19 line of diagnostics, after submission of its validation data to the New York State Department of Health (NYSDOH) in the next few days.
The Company also announced that its EUA-authorized Linea™ COVID-19 Assay Kit (the "Linea 1.0 Assay") likely exhibits a unique double S-gene target failure (or "drop") (SGTF) specific to the Omicron variant. While other assays have been shown to have SGTF based on the presence of the ?69-70 mutation contained in Omicron, this specific mutation is shared across several SARS-CoV-2 lineages and is not specific to the new variant. Based on the Company’s initial analysis, the Company believes that the combination of mutations that cause the unique double SGTF in the Linea 1.0 Assay is unique to Omicron. This unique double SGTF may result in false negative results in patients infected with the Omicron variant when tested with the Linea 1.0 Assay as a primary diagnostic. This unique pattern may, however, allow the Linea 1.0 Assay to provide a high-specificity reflex test for the Omicron variant. More specifically, the Linea 1.0 Assay may be potentially used as a reflex test to indicate the presence of Omicron in samples that have tested positive for COVID-19 via third-party assays that cannot discriminate for the new variant because these same samples will test negative on the Linea 1.0 Assay due to the unique double SGTF.
BP plans to turn Teesside into first green hydrogen hub
Emily Gosden, Energy Editor
Monday November 29 2021, 12.01am, The Times
Bernard Looney, BP’s chief executive, with the Tees Valley mayor Ben Houchen at the Teesworks freeport site where the company plans a major investment in carbon capture
Bernard Looney, BP’s chief executive, with the Tees Valley mayor Ben Houchen at the Teesworks freeport site where the company plans a major investment in carbon capture
BP
Share
Save
BP plans to build Britain’s biggest “green hydrogen” facility on Teesside to produce the clean fuel for use in new hydrogen-powered lorries and other transport.
The oil giant said its HyGreen Teesside project aimed initially to develop 60 megawatts of electrolyser capacity to produce zero-carbon hydrogen by 2025 at an estimated cost of about £100 million. This would produce enough hydrogen for 1,300 new lorries to run on the green fuel, replacing ones that burn polluting diesel.
BP then aims to expand the electrolyser capacity to as much as 500 megawatts by 2030 under plans to turn Teesside into the “UK’s first major hydrogen transport hub”.
Matthew Williamson, the BP executive leading its hydrogen projects in the UK, said: “We are talking about a broad range of transport applications: it’s trucks, trains, buses, boats, cars and planes.”
Green hydrogen is made by using renewable electricity to split water into hydrogen and oxygen by electrolysis. The biggest electrolyser planned in the UK to date is believed to be Scottish Power’s 20 megawatt project near Glasgow.
ADVERTISEMENT
BP is already planning to develop a 1 gigawatt facility on Teesside to produce “blue hydrogen”, which is produced by processing natural gas and capturing most of the waste carbon dioxide, in a process that’s low-carbon but still has some emissions. The so-called “H2Teesside” plant could cost £1 billion, excluding the offshore carbon storage infrastructure.
Combined, BP’s blue and green hydrogen facilities could provide about 30 per cent of the UK’s target of developing 5 gigawatts of low-carbon hydrogen production capacity this decade. However, the development of all the projects will be dependent on the government confirming subsidies or other support to make them economically viable.
BP is one of the world’s biggest oil and gas companies but is undergoing a radical strategic shift towards low-carbon energy, with targets to cut its oil and gas output by 40 per cent this decade while ploughing billions into wind and solar power, electric vehicle charging and hydrogen.
It aims to have a 10 per cent market share of low-carbon hydrogen supply in core markets, and is developing projects in Germany, Spain and the Netherlands. Last month it was named as preferred bidder for a much smaller green hydrogen project in Aberdeen, and also signed a partnership with Daimler Truck in which it will develop a new network of up to 25 hydrogen refuelling stations around Britain this decad
Side effects too....urrghh.
"scientists raised some concerns about molnupiravir, including around evidence from animal studies of impaired bone and cartilage growth as well as the potential for birth defects. And because molnupiravir works by introducing a series of errors into a virus' genetic code, FDA scientists questioned whether the drug might trigger unwanted long-term effects or create new coronavirus variants.
Additionally, the available safety data is limited, meaning rare side effects that haven't been detected in testing could occur when the drug is cleared for use in the broader population, FDA reviewers said."
They must be desperate to give that an EUA
there was a time when that was treasonous
SIXTY-ONE passengers out of 600 who landed in Holland from South Africa yesterday had Covid
have you seen the US futures !!!!!!!!!!!!!!
a worked trade
got the sp down to £ 4.5 and 3 x 100,000 trades = £1,350,000
bit of skin in the game
i thought Blackrock was a holder ?
please correct me if im wrong
just read previous issue of Private Eye
we got a bit of a pasting in that
dont know whether that got spotted on here or not
Pfizer, Merck, Roche, Moderna etc. buy out SNG ????
even more of a takeovertarget now !!!
but where would i get my daily chuckle
hasnt been this low for a while !